ZBTB46-AS1: A Potential Drug Target and Biomarker (G101928604)

Target Name: ZBTB46-AS1

NCBI ID: G101928604

ZBTB46-AS1

Other Name(s): ZBTB46 antisense RNA 1

ZBTB46-AS1: A Potential Drug Target and Biomarker

ZBTB46-AS1, a novel antisense RNA, has been identified as a potential drug target and biomarker for various diseases, including cancer. This RNA is derived from the ZBTB46 gene, which encodes a protein involved in cell signaling pathways, such as NF-kappa and Wnt. The expression of ZBTB46-AS1 has been shown to be downregulated in various diseases, including cancer, and its overexpression has been associated with disease progression. Therefore, targeting ZBTB46-AS1 may provide new insights into the pathogenesis and treatment of these diseases.

Targeting ZBTB46-AS1

The ZBTB46 gene encodes a protein that plays a crucial role in the development and maintenance of tissues, including neural cells and cancer cells. The protein is involved in various signaling pathways, including NF-kappa signaling, which is a critical pathway involved in cell growth, differentiation, and survival.

ZBTB46-AS1 is a non-coding RNA that has been shown to interact with the protein ZBTB46. This interaction between ZBTB46-AS1 and ZBTB46 has been shown to play a role in regulating cellular processes, including cell growth, apoptosis, and inflammation. ZBTB46-AS1 has also been shown to interact with other proteins, including NF-kappa, which may enhance its ability to modulate cellular processes.

Drug Targeting ZBTB46-AS1

The potential drug targeting of ZBTB46-AS1 is based on its role in various signaling pathways, including NF-kappa signaling. NF-kappa is a critical signaling pathway involved in cell growth, differentiation, and survival, and its dysregulation has been implicated in various diseases, including cancer. Therefore, targeting ZBTB46-AS1 may provide new insights into the pathogenesis and treatment of these diseases.

One approach to drug targeting ZBTB46-AS1 is to use small molecules that can modulate its expression levels. Small molecules that can bind to ZBTB46-AS1 and prevent its interaction with ZBTB46 have been identified and are being evaluated as potential drug targets. These small molecules can include inhibitors of the RNA polymerase II (RNA-protein interaction), which is involved in the expression of ZBTB46-AS1, or modulators of the NF-kappa complex, which are involved in the regulation of cellular processes.

Biomarker Development

The expression of ZBTB46-AS1 has been shown to be downregulated in various diseases, including cancer. Therefore, its overexpression has been associated with disease progression. The development of biomarkers for ZBTB46-AS1 may provide new insights into the pathogenesis and treatment of these diseases.

One approach to the development of biomarkers for ZBTB46-AS1 is to use techniques such as qRT-PCR, a reverse transcription polymerase technique, to measure the expression of ZBTB46-AS1 in various tissues and fluids, including cancer cells, tissues, and body fluids. The expression levels of ZBTB46-AS1 can be used as a biomarker for disease diagnosis, monitoring, and treatment.

Conclusion

ZBTB46-AS1 is a novel antisense RNA that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its interaction with the protein ZBTB46 and its role in NF-kappa signaling have been shown to play a crucial role in the development and maintenance of tissues. Therefore, targeting ZBTB46-AS1 may provide new insights into the pathogenesis and treatment of these diseases. Further research is needed to develop new biomarkers and therapeutic approaches for ZBTB46-AS1.

Protein Name: ZBTB46 Antisense RNA 1

The "ZBTB46-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBTB46-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets